These novel therapies , Semaglutide , represent a significant advancement in addressing obesity and potentially associated ailments . These drugs are classified as GLP-1 pathway agonists , meaning they to mimic the endogenous GLP-1 hormone , enhancing metabolic release and reducing appetite . Des